Achaogen Appoints John C. Doyle to the Newly Created Position of Chief Operating Officer
8/25/2009 9:32:40 AM
SAN FRANCISCO--(BUSINESS WIRE)--Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, announced today the appointment of John C. Doyle to the newly created position of chief operating officer. Mr. Doyle brings years of experience in leadership roles managing business and financial operations, strategic and operational planning, equity financing, strategic alliances and R&D program management with biotechnology companies including Genentech, Renovis and Tularik.
comments powered by